

# Cutaneous T-Cell Lymphoma - Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2025

<https://marketpublishers.com/r/CDEC236F790EN.html>

Date: November 2017

Pages: 221

Price: US\$ 6,950.00 (Single User License)

ID: CDEC236F790EN

## Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's "Cutaneous T-Cell Lymphoma – Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2025" report provides an overview of the disease, the comprehensive insights on the competitive landscape and market of Cutaneous T-Cell Lymphoma.

The Report covers detailed historical and forecasted epidemiology of Cutaneous T-Cell Lymphoma (CTCL) in the 7MM (till 2025), segmented on the basis of sub-types (Mycosis fungoides, Sezary syndrome and others i.e., Primary cutaneous peripheral T-cell lymphoma, ATLL, primary cutaneous CD30+ T-cell lymphoproliferative disorders, subcutaneous panniculitis-like T-cell lymphoma (SPTCL) and unspecified), gender (predominant in males) as well as stages of the disease (Early Stage and Late Stage).

The Report also includes market trends of the Cutaneous T-Cell Lymphoma for the seven major markets i.e., United States, EU5 (France, Germany, Italy, Spain, and UK) and Japan. The Report covers the therapeutics market revenue, treatment practice/algorithm and forecasted market size of Cutaneous T-Cell Lymphoma from 2017 to 2025 segmented by seven major markets. In addition, the report also covers market drivers, market barriers and unmet medical need.

The competitive landscape of the report covers both pipeline and marketed portfolio of the indication. Cutaneous T-Cell Lymphoma pipeline provides information on the therapeutic drugs in development and comparative analysis at various stages covering clinical and pre-clinical & discovery stages, therapeutics assessment by

Monotherapy/Combination products and Molecule Type drug analysis. It also provides in-depth analysis on the Phase III profile covering clinical trial studies, recent developments and SWOT Analysis.

The United States accounts for the highest incident population of CTCL in comparison to EU5 countries and Japan. According to DelveInsight, it is estimated that the incident cases of CTCL in the United States shall increase at a CAGR of 0.35% from 2013 to 2025.

The treatment of CTCL depends on the disease stage. Early stage therapies are topical, including corticosteroids, retinoids, imiquimod (Aldara), ultraviolet A irradiation (PUVA), and total skin electron beam therapy. Systemic therapies are introduced in the advanced stages where the disease is widespread and/or resistant to topical treatment. These include interferon alpha injections, stem cell transplant, alemtuzumab (MabCampath) and other chemotherapy regimens. The FDA approved drugs are Istodax (romidepsin), Valchlor (mechlorethamine), Uvadex (methoxsalen), Targretin (bexarotene) and Zolinza (vorinostat). The drugs have been considered in our report as per NCCN (United States) guidelines.

Amongst all the 7MM, United States accounts for highest market share for CTCL due to high incidence as well as due to high annual cost of therapy. According to DelveInsight, the Cutaneous T-Cell Lymphoma market size in 7MM is estimated to increase at a compound annual growth rate (CAGR) of 1.6% for the forecasted period i.e., 2013-2025.

## **SCOPE OF THE REPORT**

Overview of the Global pipeline scenario for Cutaneous T-Cell Lymphoma, products and associated companies information

Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with product development activities.

The Report provides detailed historical and forecasted epidemiological data of Cutaneous T-Cell Lymphoma in the 7MM i.e., United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2025.

Organize sales and marketing efforts by identifying the best opportunities for Cutaneous T-Cell Lymphoma in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.

To understand the future market competition in the global Cutaneous T-Cell Lymphoma market and Insightful review of the key market drivers and barriers.

The report will help in developing business strategies by understanding the trends shaping and driving the global Cutaneous T-Cell Lymphoma market.

Key topics covered include strategic competitor assessment, barriers and drivers in the market along with SWOT analysis

The Report also covers the detailed historical and forecasted Cutaneous T-Cell Lymphoma market covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2025.

## Contents

Report Introduction

Cutaneous T- Cell Lymphoma Market Overview at a Glance

Total Market Share Distribution of Cutaneous T- Cell Lymphoma for 7 MM in 2016

Total Market Share Distribution of Cutaneous T- Cell Lymphoma for 7 MM in 2025

Cutaneous T- Cell Lymphoma

Introduction

Types

Causes

Pathophysiology

Symptoms

Diagnosis

Epidemiology of Cutaneous T-Cell Lymphoma

United States

Assumptions and Rationale

Incident Population of Cutaneous T-Cell Lymphoma

Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in United States

Gender Specific Incidence of Cutaneous T-Cell Lymphoma in United States

Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in United States

Europe

Assumptions and Rationale

Germany

Incident Population of Cutaneous T-Cell Lymphoma in Germany

Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany

Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany

Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany

France

Incident Population of Cutaneous T-Cell Lymphoma in France

Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France

Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France

Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France

Italy

Incident Population of Cutaneous T-Cell Lymphoma in Italy

Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy

Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy

Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy

Spain

Incident Population of Cutaneous T-Cell Lymphoma in Spain

- Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain
- Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain
- Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain
- United Kingdom
  - Incident Population of Cutaneous T-Cell Lymphoma in UK
  - Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in United Kingdom
  - Gender Specific Incidence of Cutaneous T-Cell Lymphoma in United Kingdom
  - Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK
- Japan
  - Incident Population of Cutaneous T-Cell Lymphoma in Japan
  - Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan
  - Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan
  - Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan
- Treatment Algorithm
  - International Lymphoma Radiation Oncology Group Guidelines for Modern Radiation Therapy for Primary Cutaneous Lymphomas
  - United States
    - NCCN Guidelines
  - Europe
    - ESMO Guidelines
    - Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group Guidelines
  - EORTC recommendations for the treatment of mycosis fungoides/Sezary syndrome
- Unmet Needs
- Competitive Marketed Drug Landscape
  - Istodax (Romidepsin): Celgene Corporation
    - Drug Description
    - Mechanism of Action
    - Advantages & Disadvantages
    - Safety and Efficacy
    - Product Profile
  - Marketed Drug List Continued...
- Competitive Pipeline Landscape
  - Emerging Therapies
    - Brentuximab Vedotin: Seattle Genetics
      - Product Description
      - Research and Development
      - Product Development Activities
      - Product Profile

**Emerging Drug List Continued****Comparative Analysis**

Clinical Stage Products

Pre-Clinical Stage Products

**Therapeutic Assessment**

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Assessment by Domain

Assessment by Stage and Domain

**Cutaneous T- Cell Lymphoma: Country-Wise Market Analysis****Total Market Size of Cutaneous T- Cell Lymphoma for 7 MM in 2013-2025****United States**

Market Size of CTCL in United States

Stage-Specific Market Size(Early&amp;Late) of CTCL in United States

**Europe****Germany**

Market Size of CTCL in Germany

Stage-Specific Market Size(Early&amp;Late) of CTCL in Germany

**France**

Market Size of CTCL in France

Stage-Specific Market Size(Early&amp;Late) of CTCL in France

**Italy**

Market Size of CTCL in Italy

Stage-Specific Market Size(Early&amp;Late) of CTCL in Italy

**Spain**

Market Size of CTCL in Spain

Stage-Specific Market Size(Early&amp;Late) of CTCL in Spain

**United Kingdom**

Market Size of CTCL in United Kingdom

Stage-Specific Market Size(Early&amp;Late) of CTCL in United Kingdom

**Japan**

Market Size of CTCL in Japan

Stage-Specific Market Size(Early&amp;Late) of CTCL in Japan

**Market Drivers****Market Restraints**

Appendix  
Report Methodology  
Consulting Services  
Disclaimer  
About DelveInsight

## List Of Tables

### LIST OF TABLES

Table 1: Incident Population of Cutaneous T-Cell Lymphoma in United States (2013-2025)

Table 2: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in US (2013-2025)

Table 3: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in US (2013-2025)

Table 4: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in United States (2013-2025)

Table 5: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2013-2025)

Table 6: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2013-2025)

Table 7: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2013-2025)

Table 8: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2013-2025)

Table 9: Incident Population of Cutaneous T-Cell Lymphoma in France (2013-2025)

Table 10: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2013-2025)

Table 11: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2013-2025)

Table 12: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2013-2025)

Table 13: Incident Population of Cutaneous T-Cell Lymphoma Italy (2013-2025)

Table 14: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2013-2025)

Table 15: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2013-2025)

Table 16: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2013-2025)

Table 17: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2013-2025)

Table 18: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2013-2025)

Table 19: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2013-2025)

Table 20: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2013-2025)

Table 21: Incident Population of Cutaneous T-Cell United Kingdom (2013-2025)



- Table 22: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2013-2025)
- Table 23: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2013-2025)
- Table 24: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2013-2025)
- Table 25: Incident Population of Cutaneous T-Cell Japan (2013-2025)
- Table 26: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2013-2025)
- Table 27: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2013-2025)
- Table 28: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2013-2025)
- Table 29: Brentuximab Vedotin, Clinical Trials by Zone, 2017
- Table 30: Clinical Trials by Recruitment status, 2017
- Table 31: Number of Products under development by Companies, 2017
- Table 32: Clinical Stage Products, 2017
- Table 33: Pre-Clinical Stage Products, 2017
- Table 34: Assessment by Monotherapy Products, 2017
- Table 35: Assessment by Combination Products, 2017
- Table 36: Assessment by Route Of Administration, 2017
- Table 37: Assessment by Stage and Route Of Administration, 2017
- Table 38: Assessment by Molecule Type, 2017
- Table 39: Assessment by Stage and Molecule Type, 2017
- Table 40: Assessment by Stage of development and Domain, 2017
- Table 41: Recommendations for treatment of CTCL by Radiation Therapy
- Table 42: Recommendations for treatment of MF stages IA, IB, and IIA
- Table 43: List of Marketed Drugs for Cutaneous T Cell Lymphoma
- Table 44: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2013-2025)
- Table 45: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
- Table 46: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in United States in USD, Million (2013-2025)
- Table 47: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
- Table 48: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Germany in USD, Million (2013-2025)
- Table 49: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
- Table 50: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in

France in USD, Million (2013-2025)

Table 51: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)

Table 52: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Italy in USD, Million (2013-2025)

Table 53: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)

Table 54: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Spain in USD, Million (2013-2025)

Table 55: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)

Table 56: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in United Kingdom in USD, Million (2013-2025)

Table 57: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)

Table 58: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Japan in USD, Million (2013-2025)

## List Of Figures

### LIST OF FIGURES

Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in United States (2013-2025)

Figure 2: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in US (2013-2025)

Figure 3: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in US (2013-2025)

Figure 4: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in United States (2013-2025)

Figure 5: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2013-2025)

Figure 6: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2013-2025)

Figure 7: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2013-2025)

Figure 8: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2013-2025)

Figure 9: Incident Population of Cutaneous T-Cell Lymphoma in France (2013-2025)

Figure 10: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2013-2025)

Figure 11: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2013-2025)

Figure 12: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2013-2025)

Figure 13: Incident Population of Cutaneous T-Cell Lymphoma Italy (2013-2025)

Figure 14: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2013-2025)

Figure 15: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2013-2025)

Figure 16: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2013-2025)

Figure 17: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2013-2025)

Figure 18: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2013-2025)

Figure 19: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2013-2025)

Figure 20: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2013-2025)

Figure 21: Incident Population of Cutaneous T-Cell United Kingdom (2013-2025)

Figure 22: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2013-2025)

Figure 23: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2013-2025)

Figure 24: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2013-2025)

Figure 25: Incident Population of Cutaneous T-Cell Japan (2013-2025)

Figure 26: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2013-2025)

Figure 27: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2013-2025)

Figure 28: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2013-2025)

Figure 29: Brentuximab Vedotin, Clinical Trials by Zone, 2017

Figure 30: Clinical Trials by Recruitment status, 2017

Figure 31: Number of Products under development by Companies, 2017

Figure 32: Clinical Stage Products, 2017

Figure 33: Pre-Clinical Stage Products, 2017

Figure 34: Assessment by Monotherapy Products, 2017

Figure 35: Assessment by Combination Products, 2017

Figure 36: Assessment by Route Of Administration, 2017

Figure 37: Assessment by Stage and Route Of Administration, 2017

Figure 38: Assessment by Molecule Type, 2017

Figure 39: Assessment by Stage and Molecule Type, 2017

Figure 40: Assessment by Stage of development and Domain, 2017

Figure 41: Recommendations for treatment of CTCL by Radiation Therapy

Figure 42: Recommendations for treatment of MF stages IA, IB, and IIA

Figure 43: List of Marketed Drugs for Cutaneous T Cell Lymphoma

Figure 44: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2013-2025)

Figure 45: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)

Figure 46: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in United States in USD, Million (2013-2025)

Figure 47: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)

Figure 48: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Germany in USD, Million (2013-2025)

Figure 49: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million

(2013-2025)

Figure 50: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in France in USD, Million (2013-2025)

Figure 51: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)

Figure 52: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Italy in USD, Million (2013-2025)

Figure 53: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)

Figure 54: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Spain in USD, Million (2013-2025)

Figure 55: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)

Figure 56: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in United Kingdom in USD, Million (2013-2025)

Figure 57: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)

Figure 58: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Japan in USD, Million (2013-2025)

## I would like to order

Product name: Cutaneous T-Cell Lymphoma - Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2025

Product link: <https://marketpublishers.com/r/CDEC236F790EN.html>

Price: US\$ 6,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CDEC236F790EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

